Prosecution Insights
Last updated: November 12, 2026
Application No. 18/263,439

NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF

Final Rejection §103§DOUBLEPATENT
Filed
Jul 28, 2023
Priority
Feb 03, 2021 — CN 202110147730.4 +1 more
Examiner
SZPERKA, MICHAEL EDWARD
Art Unit
1641
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Imvivabio LLC
OA Round
2 (Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
603 granted / 962 resolved
+2.7% vs TC avg
Strong +37% interview lift
Without
With
+37.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
62 currently pending
Career history
1013
Total Applications
across all art units

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s response and amendments received August 19, 2026 are acknowledged. Claims 3-5, 13, 14, 16, 17, 21, 22, 27, 28, 30, and 31 have been canceled. Claims 1, 2, 6-8, 10, 18-20, 23, and 29 have been amended Claims 1, 2, 6-12, 15, 18-20, 23-26, and 29 are pending in the instant application. Applicant’s response and claim amendments have overcome all prior grounds of objection rejection as set forth in the office action mailed May 21, 2026. However, upon reconsideration the following new grounds of rejection have been set forth. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 2, 6-9, 12, 15, 18, 19, and 29 are rejected under 35 U.S.C. 103 as being unpatentable over Ge et al. (WO 2021/223359) in view of Yang et al. (WO 2019/242339). Ge et al. disclose bispecific CAR that bind CD7 and CD19 and the administration of cells expressing such CAR to treat disorders including graft versus host disease (see entire document, particularly the abstract, claims, and Figures 1-9). Notably, such constructs contained a conventional arrangement of a 4-1BB costimulatory domain followed by a CD3zeta domain (see most particularly Figures 1A and 1B and note the nomenclature “BBz” for 4-1BB-CD3zeta). Such receptors are disclosed as being transfected into various immune cells including T cell, NKT cells, NK cells, and iPSC cells (see particularly paragraph [0015] and [0126-0142]) and such cells are further disclosed as comprising inactivation of the endogenous TCR loci as well as CD7 and one or more HLA class I and class II molecules, all of which can reduce side effect of CAR administration (see particularly paragraphs [0016-0018] and [0143-0177]). Pharmaceutical compositions comprising such cells are also disclosed (see particularly paragraphs [0233-0238]). The cells of Ge et al. are further disclosed as expressing one or more enhancer moieties, such moieties including IL-2, PD-1, and PD-L1 (see for example paragraphs [0019] and [0217] and claim 45). Additionally, the CD7 binding CAR of Ge al. are based upon the 3A1F clone and comprise VL and VL sequences 100% identical to instantly recited SEQ ID NOs:7 and 8 (see enclosed sequence alignments) and that the CD19 binding portions can comprise biological sequences derived from the well-known FMC63 antibody clone (see particularly paragraph [0199]). Such claims differ from what is presently claimed in that the intracellular signaling domains of the CAR constructs of Ge et al. are not explicitly taught as additionally comprising a common gamma chain (“gc”). Yang et al. disclose chimeric antigen receptors wherein the intracellular domains of such receptors comprise a from membrane proximal to membrane distal a 4-1BB costimulatory domain, followed by a CD3zeta domain followed by the IL2Rgamma chain, other called the “common gamma chain” (gc) in the art as this polypeptide is a part of many other interleukin receptors (see entire document, particularly the abstract and Figure 1 reproduced below). PNG media_image1.png 262 520 media_image1.png Greyscale Note that SEQ ID NO:7 on page 5 of Yang et al. is 100% identical to instant SEQ ID NO:65, and that such sequences are the gamma chain of the IL-2 receptor, i.e. “gc”. Antigen specificity of the CAR is disclosed as being provided by a scFv that binds the target antigen (see again Figure 1 most explicitly). Notably, it is disclosed that cells expressing constructs comprising the common gamma chain increased survival rate in a tumor challenge model as compared to CAR constructs comprising only the 4-1BB and CD3zeta intracellular domains as readily seen by Figure 15 (reproduced below). PNG media_image2.png 255 441 media_image2.png Greyscale Therefore, it would have been obvious to ordinary artisans at the time of the invention to add the IL-2Rgamma/”gc” domain distally to the intracellular domains of the CAR of Ge et al. in order to gain the advantage of enhanced CAR activity when using such constructs as compared to those comprising only 4-1BB and CD3zeta intracellular domains as was taught by Yang et al. Claims 10 and 11 are rejected under 35 U.S.C. 103 as being unpatentable over Ge et al. (US 2023/0113157) in view of Yang et al. (WO 2019/242339) as applied to claims 1, 2, 6-9, 12, 15, 18, 19, and 29 above, and further in view of Forman et al. (US 2020/0040096). The inventions rendered obvious by the combined teachings of Ge at al. and Yang et al. have been discussed above, and differ from that which is presently claimed in that the anti-CD19 CAR is not disclosed as having the antibody biological sequences presently recited in the instant claims. Forman et al. disclose anti-CD19 CAR that comprise biological sequences from the FMC63 antibody which are identical to instant recited SEQ ID NOs:56 and 57 in instant claim 11 (see entire document particularly the abstract, claims, example 1, paragraphs [0027] and [0086], and the enclosed sequence alignments). CARs comprising the antigen binding domains of the FMC63 antibody were shown to be active and have target binding specificity in vitro and in vivo (see particularly the working examples). Therefore, it would have been obvious to a person of ordinary skill in the art to use the antigen binding domain of the CD19 CAR of Forman et al. in the CD19 binding CAR rendered obvious by the combined teachings of Ge et al. and Yang et al. as both are disclosed as being based upon the FMC63 antibody and the constructs of Forman et al. were demonstrated to work both in vitro and in vivo as taught by Forman et al. Claims 20 and 23 are rejected under 35 U.S.C. 103 as being unpatentable over Ge et al. (US 2023/0113157) in view of Yang et al. (WO 2019/242339) as applied to claims 1, 2, 6-9, 12, 15, 18, 19, and 29 above, and further in view of Bethune et al. (US 12,577,283). The inventions rendered obvious by the combined teachings of Ge at al. and Yang et al. have been discussed above, and differ from that which is presently claimed in that the CAR transfected immune cells are not disclosed as also comprising a knockout of the RFX5 gene. Bethune et al. disclose improvements to allogeneic cell therapies that provide increased persistence of the administered cells to mitigate rejection by the host or recipient (see entire document, particularly the abstract, claims and paragraphs [0007]-[0008]). They disclose that such improvements arise by silencing or suppressing one or more of TAP2, NLRC5, p2m, TRAC, CIITA, RFX5, RFXAP and RFXANK, with RAC/RFX5 double knockout T cells demonstrating enhanced survival and increased anti-tumor activity when transfected with a CD19 CAR both in vitro and in vivo (see particularly working examples 6, 7, 10, and 11). Therefore, it would have been obvious to ordinary artisans to practice the methods rendered obvious by the combined teachings of Ge et al. and Yang et al. in the setting of RFX5 knockouts. This is because Ge et al. already disclose superior efficacy of their CAR constructs in knockout cell backgrounds and knocking out the RFX5 gene is reasonably expected to add additional therapeutic efficacy based upon the anti-CD19 CAR data of Bethune et al., obtained in just such a generic background. Claims 24-26 are rejected under 35 U.S.C. 103 as being unpatentable over Ge et al. (US 2023/0113157) in view of Yang et al. (WO 2019/242339) as applied to claims 1, 2, 6-9, 12, 15, 18, 19, and 29 above, and further in view of Liao et al (of record as reference U on the 5/21/2026 form 892). The inventions rendered obvious by the combined teachings of Ge at al. and Yang et al. have been discussed above, and differ from that which is presently claimed in that the CAR transfected immune cells are not disclosed as also comprising an immunosuppressive molecule comprising a PD-1L binding domain ,a transmembrane domain, and an intracellular co-stimulatory domain. Liao et al. disclose that on-target but off-tumor (i.e. binding of the CAR to a target that expresses the antigen but isn’t a tumor) cytotoxicity is a major impediment of CAR T cell therapy, and adding a “chimeric costimulatory receptor” ligand (CCRs) to CAR expressing cells can lessen off-tumor side effects as tumor cells will over-express the ligand for the CCR while normal tissue will have minimal to no expression of the ligand for the CCR (see entire document, particular the abstract and Figure 1). To that end, they disclose combining an anti-CD19 CAR with a CCR comprising a scFv that binds PD-L1, a transmembrane domain, and the intracellular signaling domain of CD28 (see particularly the paragraph bridging pages 2 and 3 as well as Figure 1A). Cells expressing such chimeric receptors demonstrated improved proliferation and improved killing of tumor targets as compared to cells expressing only the CAR construct (see particularly the Discussion and Conclusion sections). Therefore, it would have been obvious to ordinary artisans at the time of the invention to add a CCR targeting PD-L1 to the CAR cells rendered obvious by the combined teachings of Ge et al. and Yang et al. in order to enhance the efficacy and safety of CAR cells as amply demonstrated by the teachings and data of Liao et al. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 2, 6-9, 12, 15, 18-20, 23, 29 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 and 13-20 of copending Application No. 18/034,177 in view of Yang et al. (WO 2019/242339). The copending claims recite engineered immune cells expressing a CD7 chimeric antigen receptor in a genetic background wherein expression of endogenous CD7, TRAC and RFX5 have been silenced and the cell is T cell, NK cell or NKT cell (see al claims, particularly 1, 9, 10, 11, and 16). Notably the CD7 CAR of the copending claims is recited as comprising the same biological sequences as what is recited in the instant claims (compare copending claim 3 to instant claim 7) and such cells are also recited as expressing a CD19 CAR (see particularly copending claims 4 and 5) as well as an NK inhibitor molecule (see claim 1). Pharmaceutical compositions comprising such cells are also claimed (see copending claim 17). While the copending claims do not recite nucleic acids encoding CAR, given that CAR are not naturally occurring and are transmembrane proteins, the only reasonable way that can be made is via recombinant molecular biology using nucleic acids and thus nucleic acids encoding the constructs necessarily present in the copending claims are exceedingly obvious. The copending claims differ from the instant claimed inventions in that the CAR is not disclosed as comprising a gc domain membrane distal to 4-1BB and CD3zeta domains. Yang et al. disclose chimeric antigen receptors wherein the intracellular domains of such receptors comprise a from membrane proximal to membrane distal a 4-1BB costimulatory domain, followed by a CD3zeta domain followed by the IL2Rgamma chain, other called the “common gamma chain” (gc) in the art as this polypeptide is a part of many other interleukin receptors (see entire document, particularly the abstract and Figure 1 reproduced below). PNG media_image1.png 262 520 media_image1.png Greyscale Note that SEQ ID NO:7 on page 5 of Yang et al. is 100% identical to instant SEQ ID NO:65, and that such sequences are the gamma chain of the IL-2 receptor, i.e. “gc”. Antigen specificity of the CAR is disclosed as being provided by a scFv that binds the target antigen (see again Figure 1 most explicitly). Notably, it is disclosed that cells expressing constructs comprising the common gamma chain increased survival rate in a tumor challenge model as compared to CAR constructs comprising only the 4-1BB and CD3zeta intracellular domains as readily seen by Figure 15 (reproduced below). PNG media_image2.png 255 441 media_image2.png Greyscale Therefore, it would have been obvious to ordinary artisans at the time of the invention to add the IL-2Rgamma/”gc” domain distally to the intracellular domains of the CAR of the copending claims in order to gain the advantage of enhanced CAR activity when using such constructs as compared to those comprising only 4-1BB and CD3zeta intracellular domains as was taught by Yang et al. This is a provisional nonstatutory double patenting rejection. Note that applicant has paid the issue fee in the ‘177 application but the application has not yet issued as a patent. When it does this rejection, and any based upon the ‘177 application will cease to be of a provisional nature. Claims 10 and 11 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 and 13-20 of copending Application No. 18/034,177 in view of Yang et al. (WO 2019/242339) as applied to claims 1, 2, 6-9, 12, 15, 18-20, 23, 29 above, and further in view of Forman et al. (US 2020/0040096). The inventions rendered obvious by the copending claims in view of Yang et al. have been discussed above and differ from what is presently claimed in that no sequences are recited regarding the antigen binding domain of the anti-CD19 CAR. Forman et al. disclose anti-CD19 CAR that comprise biological sequences from the FMC63 antibody which are identical to instant recited SEQ ID NOs:56 and 57 in instant claim 11 (see entire document particularly the abstract, claims, example 1, paragraphs [0027] and [0086], and the enclosed sequence alignments). CARs comprising the antigen binding domains of the FMC63 antibody were shown to be active and have target binding specificity in vitro and in vivo (see particularly the working examples). Therefore, it would have been obvious to a person of ordinary skill in the art to use the antigen binding domain of the CD19 CAR of Forman et al. in the CD19 binding CAR rendered obvious by the combined teachings the copending claims and Yang et al. This is because the copending claim recite no specific sequence whatsoever and thus some sequence would be needed to be used in preparing the non-naturally occurring engineered immune cells. Thus artisans would be motivated to use CD19 CAR sequences already demonstrated in the prior art to be effective in vitro and in vivo, such as those disclose by Forman et al. rather than undertaking the time and effort to synthesize new reagents from scratch which require additional testing concerning efficacy. Claims 24-26 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 and 13-20 of copending Application No. 18/034,177 in view of Yang et al. (WO 2019/242339) as applied to claims 1, 2, 6-9, 12, 15, 18-20, 23, 29 above, and further in view of Liao et al (of record as reference U on the 5/21/2026 form 892). The inventions rendered obvious by the combined teachings of the copending claims and Yang et al. have been discussed above, and differ from that which is presently claimed in that the CAR transfected immune cells are not disclosed as also comprising an immunosuppressive molecule comprising a PD-1L binding domain, a transmembrane domain, and an intracellular co-stimulatory domain. Liao et al. disclose that on-target but off-tumor (i.e. binding of the CAR to a target that expresses the antigen but isn’t a tumor) cytotoxicity is a major impediment of CAR T cell therapy, and adding a “chimeric costimulatory receptor” ligand (CCRs) to CAR expressing cells can lessen off-tumor side effects as tumor cells will over-express the ligand for the CCR while normal tissue will have minimal to no expression of the ligand for the CCR (see entire document, particular the abstract and Figure 1). To that end, they disclose combining an anti-CD19 CAR with a CCR comprising a scFv that binds PD-L1, a transmembrane domain, and the intracellular signaling domain of CD28 (see particularly the paragraph bridging pages 2 and 3 as well as Figure 1A). Cells expressing such chimeric receptors demonstrated improved proliferation and improved killing of tumor targets as compared to cells expressing only the CAR construct (see particularly the Discussion and Conclusion sections). Therefore, it would have been obvious to ordinary artisans at the time of the invention to add a CCR targeting PD-L1 to the CAR cells rendered obvious by the combined teachings of the copending claims and Yang et al. in order to enhance the efficacy and safety of CAR cells as amply demonstrated by the teachings and data of Liao et al. Claims 1, 2, 6-9, 12, 15, 18-20, 23, and 29 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4-17 of copending Application No. 18/861,000 in view of Ge et al. (WO 2021/223359) and in view of Yang et al. (WO 2019/242339). The copending claims recite methods for making immune cells comprising a knocked out CD7 gene followed by transfection of a CAR that binds CD7, which such CAR having the same antigen binding sequences as what are recited in the instant claims (see all copending claims, particularly claims 4, 6, 9 and 11). Such cells are further recited as comprising knockouts to additional genes including TRAC and RFX5 (see particularly claims 16 and 17). The copending claims differ from the instant claimed inventions in that the CAR is not disclosed as comprising a gc domain membrane distal to 4-1BB and CD3zeta domains. Ge et al. disclose bispecific CAR that bind CD7 and CD19 and the administration of cells expressing such CAR to treat disorders including graft versus host disease (see entire document, particularly the abstract, claims, and Figures 1-9). Notably, such constructs contained a conventional arrangement of a 4-1BB costimulatory domain followed by a CD3zeta domain (see most particularly Figures 1A and 1B and note the nomenclature “BBz” for 4-1BB-CD3zeta). Such receptors are disclosed as being transfected into various immune cells including T cell, NKT cells, NK cells, and iPSC cells (see particularly paragraph [0015] and [0126-0142]) and such cells are further disclosed as comprising inactivation of the endogenous TCR loci as well as CD7 and one or more HLA class I and class II molecules, all of which can reduce side effect of CAR administration (see particularly paragraphs [0016-0018] and [0143-0177]). Pharmaceutical compositions comprising such cells are also disclosed (see particularly paragraphs [0233-0238]). The cells of Ge et al. are further disclosed as expressing one or more enhancer moieties, such moieties including IL-2, PD-1, and PD-L1 (see for example paragraphs [0019] and [0217] and claim 45). Additionally, the CD7 binding CAR of Ge al. are based upon the 3A1F clone and comprise VL and VL sequences 100% identical to instantly recited SEQ ID NOs:7 and 8 (see enclosed sequence alignments) and that the CD19 binding portions can comprise biological sequences derived from the well-known FMC63 antibody clone (see particularly paragraph [0199]). Such claims differ from what is presently claimed in that the intracellular signaling domains of the CAR constructs of Ge et al. are not explicitly taught as additionally comprising a common gamma chain (“gc”). Yang et al. disclose chimeric antigen receptors wherein the intracellular domains of such receptors comprise a from membrane proximal to membrane distal a 4-1BB costimulatory domain, followed by a CD3zeta domain followed by the IL2Rgamma chain, other called the “common gamma chain” (gc) in the art as this polypeptide is a part of many other interleukin receptors (see entire document, particularly the abstract and Figure 1 reproduced below). PNG media_image1.png 262 520 media_image1.png Greyscale Note that SEQ ID NO:7 on page 5 of Yang et al. is 100% identical to instant SEQ ID NO:65, and that such sequences are the gamma chain of the IL-2 receptor, i.e. “gc”. Antigen specificity of the CAR is disclosed as being provided by a scFv that binds the target antigen (see again Figure 1 most explicitly). Notably, it is disclosed that cells expressing constructs comprising the common gamma chain increased survival rate in a tumor challenge model as compared to CAR constructs comprising only the 4-1BB and CD3zeta intracellular domains as readily seen by Figure 15 (reproduced below). PNG media_image2.png 255 441 media_image2.png Greyscale Therefore, it would have been obvious to ordinary artisans at the time of the invention to add the IL-2Rgamma/”gc” domain distally to the intracellular domains of the CAR of the copending claims in order to gain the advantage of enhanced CAR activity when using such constructs as compared to those comprising only 4-1BB and CD3zeta intracellular domains as was taught by Yang et al. This is a provisional nonstatutory double patenting rejection. Claims 10 and 11 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 4-17 of copending Application No. 18/861,000 in view of Ge et al. (WO 2021/223359) and in view of Yang et al. (WO 2019/242339) as applied to claims 1, 2, 6-9, 12, 15, 18-20, 23, and 29 above, and further in view of Forman et al. (US 2020/0040096). The inventions rendered obvious by the copending claims in view of Ge et al. and in view of Yang et al. have been discussed above and differ from what is presently claimed in that no sequences are recited regarding the antigen binding domain of the anti-CD19 CAR. Forman et al. disclose anti-CD19 CAR that comprise biological sequences from the FMC63 antibody which are identical to instant recited SEQ ID NOs:56 and 57 in instant claim 11 (see entire document particularly the abstract, claims, example 1, paragraphs [0027] and [0086], and the enclosed sequence alignments). CARs comprising the antigen binding domains of the FMC63 antibody were shown to be active and have target binding specificity in vitro and in vivo (see particularly the working examples). Therefore, it would have been obvious to a person of ordinary skill in the art to use the antigen binding domain of the CD19 CAR of Forman et al. in the CD19 binding CAR rendered obvious by the combined teachings the copending claims, Ge et al. and Yang et al. This is because the copending claim recite no specific sequence whatsoever and thus some sequence would be needed to be used in preparing the non-naturally occurring engineered immune cells. Thus artisans would be motivated to use CD19 CAR sequences already demonstrated in the prior art to be effective in vitro and in vivo, such as those disclose by Forman et al. rather than undertaking the time and effort to synthesize new reagents from scratch which require additional testing concerning efficacy. This is a provisional nonstatutory double patenting rejection. Claims 24-26 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 and 13-20 of copending Application No. 18/034,177 in view of Yang et al. (WO 2019/242339) as applied to claims 1, 2, 6-9, 12, 15, 18-20, 23, and 29 above, and further in view of Liao et al (of record as reference U on the 5/21/2026 form 892). The inventions rendered obvious by the combined teachings of the copending claims Ge et al. and Yang et al. have been discussed above, and differ from that which is presently claimed in that the CAR transfected immune cells are not disclosed as also comprising an immunosuppressive molecule comprising a PD-1L binding domain, a transmembrane domain, and an intracellular co-stimulatory domain. Liao et al. disclose that on-target but off-tumor (i.e. binding of the CAR to a target that expresses the antigen but isn’t a tumor) cytotoxicity is a major impediment of CAR T cell therapy, and adding a “chimeric costimulatory receptor” ligand (CCRs) to CAR expressing cells can lessen off-tumor side effects as tumor cells will over-express the ligand for the CCR while normal tissue will have minimal to no expression of the ligand for the CCR (see entire document, particular the abstract and Figure 1). To that end, they disclose combining an anti-CD19 CAR with a CCR comprising a scFv that binds PD-L1, a transmembrane domain, and the intracellular signaling domain of CD28 (see particularly the paragraph bridging pages 2 and 3 as well as Figure 1A). Cells expressing such chimeric receptors demonstrated improved proliferation and improved killing of tumor targets as compared to cells expressing only the CAR construct (see particularly the Discussion and Conclusion sections). Therefore, it would have been obvious to ordinary artisans at the time of the invention to add a CCR targeting PD-L1 to the CAR cells rendered obvious by the combined teachings of the copending claims, Ge et al. and Yang et al. in order to enhance the efficacy and safety of CAR cells as amply demonstrated by the teachings and data of Liao et al. This is a provisional nonstatutory double patenting rejection. No claims are allowable. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Szperka whose telephone number is (571)272-2934. The examiner can normally be reached Monday-Friday 8:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Misook Yu can be reached at 571-272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Michael Szperka Primary Examiner Art Unit 1641 /MICHAEL SZPERKA/ Primary Examiner, Art Unit 1641
Read full office action

Prosecution Timeline

Jul 28, 2023
Application Filed
May 21, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT
Aug 19, 2026
Response Filed
Oct 29, 2026
Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788797
METHODS FOR PREVENTING OR TREATING ALLERGY BY ADMINISTERING AN IL-4R ANTAGONIST
3y 2m to grant Granted Nov 10, 2026
Patent 12779014
ANTICOAGULANT PROTEINS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH THE ACTIVATION OF NEUTROPHILS
1y 5m to grant Granted Nov 03, 2026
Patent 12758612
GROWTH DIFFERENTIATION FACTOR 15 COMBINATION THERAPY
5y 1m to grant Granted Oct 13, 2026
Patent 12760114
NOVEL ANTI-GLYCAN ANTIBODY AND USE THEREOF
3y 6m to grant Granted Oct 13, 2026
Patent 12753245
LUCIFERASE LINKED IMMUNOSORBENT ASSAY
3y 11m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+37.4%)
Moderate
PTA Risk
Based on 962 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month